Literature DB >> 26420968

Predictive value of quantitative contrast-enhanced ultrasound in hepatocellular carcinoma recurrence after ablation.

Yi Gao1, Dong-Yan Zheng1, Zheng Cui1, Yan Ma1, Yuan-Zhi Liu1, Wei Zhang1.   

Abstract

AIM: To investigate the relationship between contrast-enhanced ultrasound (CEUS), basic fibroblast growth factor (bFGF), endothelin-1 (ET-1), and hepatocellular carcinoma (HCC) recurrence after ablation.
METHODS: A total of 51 HCC patients (38 males and 13 females) who received radiofrequency ablation in our hospital from June 2012 to July 2014 were enrolled in this study. The patients were divided into two groups: recurrence group and non-recurrence group. Routine abdominal examination was first performed in the horizontal position. Then the patients underwent CEUS and immunohistochemical staining before receiving radiofrequency ablation. All patients were followed-up every three months for one year. The results of CEUS and serum tumor marker levels were evaluated and combined together to estimate HCC recurrence and metastasis. Patients were divided into two groups: recurrence group and non-recurrence group. Quantitative parameters of CEUS and tumor expression levels of bFGF and ET-1 were compared between the two groups, respectively. Binary logistic regression analysis was used to analyze the relationship between CEUS quantitative parameters, expression levels of ET-1 and bFGF, and HCC recurrence after ablation.
RESULTS: Based on the quantitative parameters of CEUS before patients received radiofrequency ablation, the levels of tumor rise time (tRT), tumor time to peak (tTTP), tumor peak intensity (tPI) and tumor-parenchymal peak intensity (t-pPI) in the recurrence group were significantly lower than those in the non-recurrence group (16.6 ± 6.1 vs 23.2 ± 7.0, P = 0.000; 41.2 ± 10.2 vs 59.6 ± 14.2, P = 0.000; 23.8 ± 6.7 vs 31.4 ± 6.4, P = 0.000; 7.1 ± 3.4 vs 14.6 ± 7.4, P = 0.000; respectively). The expression levels of bFGF in the recurrence group were significantly higher than those in the non-recurrence group (P < 0.05). Levels of tTTP showed a significant inverse correlation with the level of bFGF in tumors (r = -0.312, P = 0.037). The Binary logistic regression analysis results revealed that the levels of tRT, tTTP, tPI and the level of bFGF were associated with HCC recurrence after radiofrequency ablation (P < 0.05).
CONCLUSION: CEUS is a noninvasive and effective method for evaluating the angiogenesis of HCC, and predicting its recurrence and prognosis.

Entities:  

Keywords:  Contrast-enhanced ultrasonography; Hepatocellular carcinoma; Radiofrequency ablation

Mesh:

Substances:

Year:  2015        PMID: 26420968      PMCID: PMC4579888          DOI: 10.3748/wjg.v21.i36.10418

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

1.  Diagnostic accuracy of CEUS in the differential diagnosis of small (≤ 20  mm) and subcentimetric (≤ 10  mm) focal liver lesions in comparison with histology. Results of the DEGUM multicenter trial.

Authors:  D Strobel; T Bernatik; W Blank; A Schuler; C Greis; C F Dietrich; K Seitz
Journal:  Ultraschall Med       Date:  2011-12-09       Impact factor: 6.548

2.  Chemoembolization for intermediate HCC: is there proof of survival benefit?

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  J Hepatol       Date:  2011-10-17       Impact factor: 25.083

3.  Antiangiogenic potential of three triterpenic acids in human liver cancer cells.

Authors:  Chun-Che Lin; Chun-Yin Huang; Mei-Chin Mong; Chien-Yi Chan; Mei-Chin Yin
Journal:  J Agric Food Chem       Date:  2010-12-22       Impact factor: 5.279

4.  Newly developed novel ultrasound technique, defect reperfusion ultrasound imaging, using sonazoid in the management of hepatocellular carcinoma.

Authors:  Masatoshi Kudo; Kinuyo Hatanaka; Kiyoshi Maekawa
Journal:  Oncology       Date:  2010-07-08       Impact factor: 2.935

Review 5.  Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis.

Authors:  Irene Floriani; Valter Torri; Eliana Rulli; Daniela Garavaglia; Anna Compagnoni; Luca Salvolini; Andrea Giovagnoni
Journal:  J Magn Reson Imaging       Date:  2010-01       Impact factor: 4.813

6.  Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study.

Authors:  Jun Luo; Rong-Ping Guo; Eric C H Lai; Yao-Jun Zhang; Wan Yee Lau; Min-Shan Chen; Ming Shi
Journal:  Ann Surg Oncol       Date:  2010-09-14       Impact factor: 5.344

7.  Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in GIST patients treated with masatinib.

Authors:  Nathalie Lassau; Linda Chami; Serge Koscielny; Mohamed Chebil; Christophe Massard; Baya Benatsou; Sophie Bidault; Angela Cioffi; Jean-Yves Blay; Axel Le Cesne
Journal:  Invest New Drugs       Date:  2010-12-07       Impact factor: 3.850

8.  Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database.

Authors:  Tania M Welzel; Barry I Graubard; Stefan Zeuzem; Hashem B El-Serag; Jessica A Davila; Katherine A McGlynn
Journal:  Hepatology       Date:  2011-06-30       Impact factor: 17.425

9.  Gadolinium-loaded polymeric nanoparticles modified with Anti-VEGF as multifunctional MRI contrast agents for the diagnosis of liver cancer.

Authors:  Yongjun Liu; Zhijin Chen; Chunxi Liu; Dexin Yu; Zaijun Lu; Na Zhang
Journal:  Biomaterials       Date:  2011-04-24       Impact factor: 12.479

10.  Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound.

Authors:  Maria Assunta Zocco; Matteo Garcovich; Andrea Lupascu; Enrico Di Stasio; Davide Roccarina; Brigida Elenora Annicchiarico; Laura Riccardi; Maria Elena Ainora; Francesca Ponziani; Gianluigi Caracciolo; Gian Lodovico Rapaccini; Raffaele Landolfi; Massimo Siciliano; Maurizio Pompili; Antonio Gasbarrini
Journal:  J Hepatol       Date:  2013-06-25       Impact factor: 25.083

View more
  5 in total

1.  (125)I-labeled anti-bFGF monoclonal antibody inhibits growth of hepatocellular carcinoma.

Authors:  Peng-Hui Hu; Lan-Hong Pan; Patrick Ting-Yat Wong; Wen-Hui Chen; Yan-Qing Yang; Hong Wang; Jun-Jian Xiang; Meng Xu
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

2.  The value of contrast-enhanced ultrasound in predicting postoperative recurrence of hepatocellular carcinoma: A protocol for systematic review and meta-analysis.

Authors:  Jieying Fu; Jia Tang; Huan Luo; Wencui Wu
Journal:  Medicine (Baltimore)       Date:  2021-06-04       Impact factor: 1.817

3.  Preoperative color Doppler ultrasonography predicts early recurrence in AFP-positive hepatocellular carcinoma.

Authors:  Miao Chen; Duo Wang; Yuan Zhao; Dan-Mei Lu; Hong-Xue Li; Jun-Jie Liu; Hang Li
Journal:  Oncol Lett       Date:  2019-09-09       Impact factor: 2.967

Review 4.  Contrast-Enhanced Ultrasound for Monitoring Treatment Response in Different Stages of Hepatocellular Carcinoma.

Authors:  Mariella Faccia; Matteo Garcovich; Maria Elena Ainora; Laura Riccardi; Maurizio Pompili; Antonio Gasbarrini; Maria Assunta Zocco
Journal:  Cancers (Basel)       Date:  2022-01-18       Impact factor: 6.639

Review 5.  Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?

Authors:  E Una Cidon; P Alonso; B Masters
Journal:  Clin Med Insights Oncol       Date:  2016-04-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.